ストックスクリーナーアプリを入手
11.27
2.45%
0.27
アフターアワーズ：
11.46
0.19
+1.69%
前日終値:
$11.00
開ける：
$11.1
24時間の取引高:
6,786
Relative Volume:
0.27
時価総額：
$56.15M
収益：
-
当期純損益:
$-12.49M
株価収益率:
-3.8013
EPS:
-2.9648
ネットキャッシュフロー:
$-5.93M
1週間 パフォーマンス:
+2.92%
1か月 パフォーマンス:
-1.23%
6か月 パフォーマンス:
+2.08%
1年 パフォーマンス:
-26.44%
1日の値動き範囲:
$10.95
$11.50
1週間の範囲:
$10.80
$11.60
52週間の値動き範囲:
$8.4801
$18.17
Mink Therapeutics Inc Stock (INKT) Company Profile
Compare INKT vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
11.27 | 56.59M | 0 | -12.49M | -5.93M | -2.9648 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-07-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc (INKT) 最新ニュース
MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript - Sahm
H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research - MarketBeat
MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript - AOL.com
MiNK Therapeutics (NASDAQ:INKT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
MiNK Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
MiNK Therapeutics, Inc. (INKT) Presents at 2026 Military Health System Research SymposiumSlideshow - Seeking Alpha
MiNK Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
META_TITLE_QUOTE - Yahoo Finance
MiNK Therapeutics Q2 Earnings Call Highlights - MarketBeat
MiNK Therapeutics Q2 Results: Net loss narrows to $3.1M, cash at $8.8M - scanx.trade
INKT: Advanced phase II ARDS trial and global access for agenT-797, with stable financials - TradingView
MiNK Therapeutics (INKT.US) will release its earnings report after market close on August 13. - 富途牛牛
Earnings call transcript: MiNK Therapeutics narrows Q2 2026 loss as trial advances - Investing.com
Transcript : MiNK Therapeutics, Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
INKT: Phase II trial for agenT-797 in ARDS shows early promise; global access and financial discipline maintained - TradingView
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury - Investing News Network
Form 8K Mink Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
MiNK Therapeutics reports Phase 2 trial data for agenT-797 By Investing.com - Investing.com Australia
MiNK Therapeutics reports Phase 2 trial data for agenT-797 - Investing.com
MiNK Reports $3.1 Million Second-Quarter Loss and Phase 2 ARDS Update - Quiver Quantitative
MiNK Therapeutics Q2 loss narrows on expense discipline - TradingView
Mink Therapeutics Inc (INKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mink Therapeutics Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates - Investing News Network
MiNK Therapeutics, Inc. (INKT) Stock: Climbs on Encouraging Phase 2 Data for agenT-797 in Severe Pneumonia - Blockonomi
Transactions récentes par des initiés de Mink Therapeutics Inc. R (6Q40.F) - Yahoo Finance France
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium - GlobeNewswire
Liquidity Mapping Around (INKT) Price Events - Stock Traders Daily
MiNK Therapeutics to Report Second Quarter 2026 Financial Results and Provide Corporate Update on agenT-797 Clinical Progress - Quiver Quantitative
MiNK Therapeutics to Report Second Quarter 2026 Financial - GlobeNewswire
New agenT-797 lung-injury data due from MiNK Aug. 13 - Stock Titan
MiNK Therapeutics (INKT) Projected to Post Earnings on Thursday - MarketBeat
Mink Therapeutics to report Q2 results, host conference call and webcast - Bitget
INKT Q2'26 Earnings: revenue estimate is 0 USD - TradingView
MiNK Therapeutics (INKT) Climbs 5.7% as Biotech Momentum BuildsStraddle Setup - dars.gov.et
MiNK Therapeutics Q1 2026 Earnings: Narrower Loss than Expected Reflects Cost DisciplineQuarterly Earnings - dars.gov.et
Mink Therapeutics Inc (INKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mink Therapeutics Inc (INKT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mink Therapeutics Inc (INKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Mink Therapeutics Inc (INKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
INKT|Mink Therapeutics Inc|Price:11.070|Chg%:+0.700 - TradingKey
TradingKey - TradingKey
Mink Therapeutics Inc (INKT) Balance Sheet - TradingKey
Mink Therapeutics Inc (INKT) Income Statement - TradingKey
MiNK Therapeutics, Inc. Revenue Breakdown – FWB:6Q40 - TradingView
Mink Therapeutics Inc (INKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mink Therapeutics Inc (INKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MiNK Therapeutics, Inc. Revenue Breakdown – MUN:6Q40 - TradingView
INKT|Mink Therapeutics Inc|Price:10.600|Chg%:-0.470 - TradingKey
INKT|Mink Therapeutics Inc|Price:11.310|Chg%:+0.620 - TradingKey
Mink Therapeutics Inc (INKT) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):